| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | B4GALT6 |
| Uniprot No | Q9UBX8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-382aa |
| 氨基酸序列 | MSVLRRMMRVSNRSLLAFIFFFSLSSSCLYFIYVAPGIANTYLFMVQARGIMLRENVKTIGHMIRLYTNKNSTLNGTDYPEGNNSSDYLVQTTTYLPENFTYSPYLPCPEKLPYMRGFLNVNVSEVSFDEIHQLFSKDLDIEPGGHWRPKDCKPRWKVAVLIPFRNRHEHLPIFFLHLIPMLQKQRLEFAFYVIEQTGTQPFNRAMLFNVGFKEAMKDSVWDCVIFHDVDHLPENDRNYYGCGEMPRHFAAKLDKYMYILPYKEFFGGVSGLTVEQFRKINGFPNAFWGWGGEDDDLWNRVHYAGYNVTRPEGDLGKYKSIPHHHRGEVQFLGRYKLLRYSKERQYIDGLNNLIYRPKILVDRLYTNISVNLMPELAPIEDY |
| 分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人β-1.4半乳糖基转移酶6(B4GALT6)的示例参考文献(示例内容供参考，需结合实际文献调整)：
---
1. **文献名称**: *B4GALT6-mediated glycosylation drives breast cancer progression via EGFR signaling*
**作者**: Smith, J. et al. (2020)
**摘要**: 本研究发现，B4GALT6在乳腺癌组织中显著高表达，通过调控EGFR受体的N-糖基化修饰，增强下游MAPK信号通路激活，从而促进肿瘤细胞增殖和转移。基因敲除B4GALT6可抑制小鼠移植瘤生长。
---
2. **文献名称**: *Structural and functional analysis of human B4GALT6 reveals key residues for substrate binding*
**作者**: Johnson, R. et al. (2018)
**摘要**: 通过X射线晶体学解析了重组人B4GALT6的催化结构域三维结构，发现其活性中心的关键氨基酸残基(如Asp254和His302)对UDP-半乳糖和受体底物结合至关重要，为开发特异性抑制剂提供了结构基础。
---
3. **文献名称**: *B4GALT6 deficiency alters sphingolipid metabolism and exacerbates neurodegeneration in Alzheimer's models*
**作者**: Brown, A. et al. (2019)
**摘要**: 在阿尔茨海默病小鼠模型中，B4GALT6表达下降导致鞘脂代谢异常，β-淀粉样蛋白沉积增加。补充重组B4GALT6蛋白可部分恢复神经细胞鞘糖脂合成，减缓认知功能退化。
---
4. **文献名称**: *Regulation of B4GALT6 by pro-inflammatory cytokines in hepatic fibrosis*
**作者**: Zhang, Y. et al. (2021)
**摘要**: 研究揭示了TNF-α和IL-6通过NF-κB通路上调肝星状细胞中B4GALT6表达，促进胶原蛋白的糖基化修饰及纤维化进程。提示B4GALT6可能成为肝纤维化治疗的新靶点。
---
**说明**：以上为示例性内容，实际引用需检索PubMed、Web of Science等数据库获取真实文献。建议使用关键词“B4GALT6”“glycosylation”“cancer”“structure”等筛选近5年研究。
B4GALT6 (β-1.4-galactosyltransferase 6) is a key enzyme in the glycosylation process, catalyzing the transfer of galactose to acceptor molecules via β-1.4 linkages. It belongs to the glycosyltransferase family and is primarily involved in synthesizing glycan structures on glycoproteins, glycolipids, and proteoglycans. Located in the Golgi apparatus, B4GALT6 plays a critical role in the biosynthesis of glycosphingolipids, including lactosylceramide and ganglioside GA2. which are essential for cell membrane integrity, cell-cell interactions, and signaling pathways.
The enzyme is encoded by the B4GALT6 gene on human chromosome 18q12.1. Structurally, it is a type II membrane protein with a short N-terminal cytoplasmic domain, a transmembrane region, and a catalytic C-terminal domain. Dysregulation of B4GALT6 has been linked to various pathological conditions. For instance, its overexpression is associated with cancer progression, particularly in enhancing tumor cell invasiveness and metastasis. Conversely, mutations in B4GALT6 are implicated in rare congenital disorders affecting glycosylation, such as hereditary spastic paraplegia and skeletal abnormalities.
Research on recombinant B4GALT6 focuses on elucidating its enzymatic mechanisms, substrate specificity, and role in disease pathways. Recombinant forms are utilized in structural studies and drug development, aiming to target glycosylation-related diseases. Its therapeutic potential includes modulating immune responses and designing glycan-based biomarkers for diagnostics. Ongoing studies aim to harness B4GALT6’s functions for biomedical applications while addressing challenges in glycoengineering and personalized medicine.
×
